Glioma Recurrence Versus Radiation Necrosis

Jena, Amarnath; Taneja, Sangeeta; Gambhir, Aashish; Mishra, Anil K.; D’Souza, Maria; Verma, Sapna; Hazari, Puja Panwar; Negi, Pradeep; Jhadav, Ganesh Krishna Rao; Sogani, Shanti Kumar

doi:10.1097/rlu.0000000000001152

Cited by 67 publications

(38 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cho/Cr ratio accuracy was 97%, and combined 18 F-FET TBRmean, rCBV and Cho/Cr ratio produced the maximum area under the curve (AUC) (Jena et al, 2016). In more recent study by Hojjati et al (2018) to differentiate GBM recurrent from post-radiation necrosis, they found that combining the data from FDG-PET/MRI with the perfusion MRI resulted in an area under the curve of 1.0, indicating highest sensitivity and specificity (Hojjati et al, 2018).…”

Section: Prognosismentioning

confidence: 99%

Combined PET/MRI in brain glioma imaging

Almansory

Fraioli

2019

Br J Hosp Med

View full text Add to dashboard Cite

Gliomas are the most common primary brain tumours in children and adults, consisting of a heterogeneous group of neoplastic diseases arise from the supporting cells of the CNS (glial cells). Their histopathological and molecular characteristics vary considerably as do their management and prognosis. Conventional gadolinium-enhanced magnetic resonance imaging (MRI) is considered the primary imaging modality for initial work up and follow up of patients with gliomas, although it has some limitations, especially in differentiating high from low grade tumours and in distinguishing disease recurrence from post-therapy changes. Hybrid positron emission tomography (PET)/MRI is a relatively novel tool that combines MRI sequences with metabolic information from PET, and therefore different PET radiotracers, in a single scan. This article discusses the main advantages and disadvantages of combined PET/MRI compared to other conventional or more widely available imaging tools, such as MRI or combined positron emission tomography–computed tomography. The main uses of PET/MRI and the most commonly used PET radiotracers in providing diagnostic, prognostic and predictive information in patients with glioma are covered.

show abstract

Section: Prognosismentioning

confidence: 99%

Combined PET/MRI in brain glioma imaging

Almansory

Fraioli

2019

Br J Hosp Med

View full text Add to dashboard Cite

show abstract

“…For the differentiation of treatment-related changes from tumor relapse, amino acid PET also provides valuable diagnostic information. Using [ 18 F]FET or [ 18 F]FDOPA, especially the differentiation of radiation injury from tumor relapse in glioma patients, as well as in patients with brain metastases, can be obtained with a relatively high diagnostic accuracy between 80-90% ( Figure 2) [11,26,[67][68][69][70][71][72][73][74][75][76][77][78][79][80]. Importantly, in glioma patients, parameters derived from dynamic [ 18 F]FET PET acquisition may further increase the diagnostic accuracy [67,[74][75][76]78].…”

Section: Value Of Amino Acid Pet Tracers For Brain Tumor Patientsmentioning

confidence: 99%

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

et al. 2020

View full text Add to dashboard Cite

The number of positron-emission tomography (PET) tracers used to evaluate patients with brain tumors has increased substantially over the last years. For the management of patients with brain tumors, the most important indications are the delineation of tumor extent (e.g., for planning of resection or radiotherapy), the assessment of treatment response to systemic treatment options such as alkylating chemotherapy, and the differentiation of treatment-related changes (e.g., pseudoprogression or radiation necrosis) from tumor progression. Furthermore, newer PET imaging approaches aim to address the need for noninvasive assessment of tumoral immune cell infiltration and response to immunotherapies (e.g., T-cell imaging). This review summarizes the clinical value of the landscape of tracers that have been used in recent years for the above-mentioned indications and also provides an overview of promising newer tracers for this group of patients.

show abstract

“…However, TBRmax (or TBRmean) with Cho/Cr ratio yielded the highest accuracy, approaching up to 97%. Their findings suggested that FET uptake with Cho/Cr ratio and normalized rCBVmean could be most useful in distinguishing primary glioma recurrence from radiation necrosis [39].…”

Section: Brain Tumoursmentioning

confidence: 99%

“…The potential role of hybrid gadolinium (Gd)-enhanced FET-PET/MR in distinguishing brain tumour recurrence Ciarmiello et al from radiation necrosis was investigated by Jena et al [39]. They analysed twenty-six patients with single or multiple contrast-enhancing brain lesions on MR after surgery and radiation therapy.…”

Section: Brain Tumoursmentioning

confidence: 99%

MR-Based Attenuation Correction in Brain PET/MR Studies: A Short Review

Giovannini¹,

Giovacchini²,

Nicolosi³

et al. 2017

J Diagn Imaging Ther

View full text Add to dashboard Cite

In the previous few years we have witnessed to an increased diffusion of positron emission tomography/magnetic resonance (PET/MR) tomographs and equally an increasing number of clinical studies with these hybrid devices in both the neurological and psychiatric fields. Although PET/MR contains many features that facilitate its application in brain imaging, accurate quantification is still hindered by difficulties in developing MR-based attenuation correction methods. In this paper, we have reviewed the three main methods currently used for attenuation correction in PET/MR: namely segmentation-based methods including, atlas and template. In addition to procedures based on the combination of PET emission data and MR anatomical information (or reconstruction-based methods). Many research centers are actively working to refine available methods and substantial improvements are expected in future years. Clinical studies using PET/MR focused mainly on neurooncological and neurodegenerative disorders. Simultaneous PET/MR was shown to provide very promising scientific results and to be logistically more convenient for patients. More studies are expected in the near future, as the availability of PET/MR and the clinical use of new tracers for neurodegenerative disorders will further increase.

show abstract

Glioma Recurrence Versus Radiation Necrosis

Cited by 67 publications

References 35 publications

Combined PET/MRI in brain glioma imaging

Combined PET/MRI in brain glioma imaging

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

MR-Based Attenuation Correction in Brain PET/MR Studies: A Short Review

Contact Info

Product

Resources

About